PODD
SURGICAL & MEDICAL INSTRUMENTS & APPARATUSInsulet Corporation - Common Stock (PODD) [ST]
www.insulet.com ↗▲ 0.51%
prev close
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+0
1 buys · 1 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2026-09-18 | PODDInsulet Corporation - Common Stock | Sell | $1,001 - $15,000 | 8d ago | — | |
| 2026-08-18 | PODDInsulet Corporation - Common Stock | Buy | $1,001 - $15,000 | 40d ago | — |
2026-09-18
Gilbert Cisneros
PODD
Amount
$1,001 - $15,000
Filed
8d ago
2026-08-18
Gilbert Cisneros
PODD
Amount
$1,001 - $15,000
Filed
40d ago
Recent News
Powered by Polygon.io
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Here's Why Insulet (PODD) is a Strong Growth Stock
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Blaize Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BZAI
ROSEN, A NATIONALLY RECOGNIZED LAW FIRM, Encourages Hyliion Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HYLN
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2026-09-18 · Sale
$1,001 - $15,000
Gilbert Cisneros
2026-08-18 · Purchase
$1,001 - $15,000